Pharmacogenomics: Advancing Evidence-Based Personalized Medicine

2014 ◽  
pp. 883-930
Keyword(s):  
Personalized Medicine ◽  
Evidence Based

scholarly journals An evidence‐based framework for evaluating pharmacogenomics knowledge for personalized medicine

2021 ◽  
Author(s):  
Michelle Whirl‐Carrillo ◽  
Rachel Huddart ◽  
Li Gong ◽  
Katrin Sangkuhl ◽  
Caroline F. Thorn ◽  
...  
Keyword(s):  
Personalized Medicine ◽  
Evidence Based

Scoring atherosclerosis in the search of evidence-based personalized medicine

2018 ◽  
Vol 261 ◽  
pp. 30-31 ◽  
Author(s):  
Fabrizio Ricci ◽  
Raffaele De Caterina ◽  
Marco Zimarino
Keyword(s):  
Personalized Medicine ◽  
Evidence Based

scholarly journals Mental disorders of known aetiology and precision medicine in psychiatry: a promising but neglected alliance

2016 ◽  
Vol 47 (2) ◽  
pp. 193-197 ◽  
Author(s):  
D. Fraguas ◽  
C. M. Díaz-Caneja ◽  
M. W. State ◽  
M. C. O'Donovan ◽  
R. E. Gur ◽  
...  
Keyword(s):  
Personalized Medicine ◽  
Mental Disorders ◽  
Precision Medicine ◽  
Psychiatric Disorders ◽  
Evidence Based Medicine ◽  
Prediction Models ◽  
Deletion Syndrome ◽  
Clinical Approach ◽  
Evidence Based ◽  
Based Medicine

Personalized or precision medicine is predicated on the assumption that the average response to treatment is not necessarily representative of the response of each individual. A commitment to personalized medicine demands an effort to bring evidence-based medicine and personalized medicine closer together. The use of relatively homogeneous groups, defined using a priori criteria, may constitute a promising initial step for developing more accurate risk-prediction models with which to advance the development of personalized evidence-based medicine approaches to heterogeneous syndromes such as schizophrenia. However, this can lead to a paradoxical situation in the field of psychiatry. Since there has been a tendency to loosely define psychiatric disorders as ones without a known aetiology, the discovery of an aetiology for psychiatric syndromes (e.g. 22q11.2 deletion syndrome in some cases of schizophrenia), while offering a path toward more precise treatments, may also lead to their reclassification away from psychiatry. We contend that psychiatric disorders with a known aetiology should not be removed from the field of psychiatry. This knowledge should be used instead to guide treatment, inasmuch as psychotherapies, pharmacotherapies and other treatments can all be valid approaches to mental disorders. The translation of the personalized clinical approach inherent to psychiatry into evidence-based precision medicine can lead to the development of novel treatment options for mental disorders and improve outcomes.

Proteomics in Personalized Medicine

2018 ◽  
pp. 80-98
Author(s):  
Srijan Goswami
Keyword(s):  
Personalized Medicine ◽  
Holistic Approach ◽  
Modern Medicine ◽  
Historical Background ◽  
Evidence Based ◽  
Future Prospects ◽  
Clinical Safety ◽  
Medical Concepts ◽  
And Personalized Medicine

The idea of personalized medicine system is an evolution of holistic approach of treatment and in more evidence based manner. The chapter begins with an introduction of how body system works naturally and impact of modern medicine on overall health, followed by a historical background and brief review of literature providing the description that the concept of personalized medicine is not new but a very old ideology which stayed neglected until the development in the field of medical genetics, followed by the role of omics in modern medicine, the comparison of modern medicine and personalized medicine, medical concepts relevant to proteomics in personalized medicine, impact of proteomics in drug development and clinical safety and finally closing the chapter with future prospects and challenges of proteomics in personalized medicine.

Nanotheranostics in Evidence Based Personalized Medicine

2014 ◽  
Vol 15 (10) ◽  
pp. 915-930 ◽  
Author(s):  
Sushil Sharma
Keyword(s):  
Drug Delivery ◽  
Drug Discovery ◽  
Cardiovascular Diseases ◽  
Personalized Medicine ◽  
Neurodegenerative Diseases ◽  
Evidence Based ◽  
Significant Information ◽  
Clinically Significant ◽  
The Right ◽  
Novel Drug

Efficient drug delivery systems are exceedingly important for novel drug discovery. The evidence-based personalized medicine (EBPM) promises to deliver the right drug at the right time to a right patient as it covers clinicallysignificant genetic predisposition and chronopharmacological aspects of nanotheranostics. Recently nanotechnology has provided clinically-significant information at the cellular, molecular, and genetic level to facilitate evidence-based personalized treatment. Particularly drug encapsulation in pegylated liposomes has improved pharmacodynamics of cancer, cardiovascular diseases, and neurodegenerative diseases. Long-circulating liposomes and block copolymers concentrate slowly via enhanced permeability and retention (EPR) effect in the solid tumors and are highly significant for the drug delivery in cancer chemotherapeutics. Selective targeting of siRNA and oligonucleotides to tumor cells with a potential to inhibit multi-drug resistant (MDR) malignancies has also shown promise. In addition, implantable drug delivery devices have improved the treatment of several chronic diseases. Recently, microRNA, metallothioneins (MTs), α-synuclein index, and Charnoly body (CB) have emerged as novel drug discovery biomarkers. Hence CB antagonists-loaded ROSscavenging targeted nanoparticles (NPs) may be developed for the treatment of neurodegenerative and cardiovascular diseases. Nonspecific induction of CBs in the hyper-proliferative cells may cause alopecia, gastrointestinal tract (GIT) symptoms, myelosuppression, neurotoxicity, and infertility. Therefore selective CB agonists may be developed to augment cancer stem cell specific CB formation to eradicate MDR malignancies with minimum or no adverse effects. This review highlights recent advances on safe, economical, and effective treatment of neurodegenerative diseases, cardiovascular diseases, and cancer by adopting emerging nanotheranostic strategies to accomplish EBPM.

Sign in / Sign up

Export Citation Format

Share Document